Trials with BPI-1178
Every colorectal cancer trial that includes this drug. Those looking for patients come first.
Showing 1–1 of 1
NCT04282031
BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4(CDK4)and CDK6 kinase activity. This Phase I study is a first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, and pharmacoki…